Overview

A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China

Status:
Recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

This is a preliminary exploratory cohort study to evaluate safety, tolerability and immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in participants aged 18 years and over in China.

Phase:

N/A

Details

Lead Sponsor:

AIM Vaccine Co., Ltd.

Collaborators:

First Affiliated Hospital Bengbu Medical College
Ningbo Rongan Biological Pharmaceutical Co. Ltd

Treatments:

Vaccines